Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
42,194,093
-
Number of holders
-
39
-
Total 13F shares, excl. options
-
12,759,585
-
Shares change
-
+12,759,585
-
Total reported value, excl. options
-
$523,637,183
-
Value change
-
+$523,637,191
-
Number of buys
-
39
-
Price
-
$41.33
Significant Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) as of Q4 2020
39 filings reported holding TARS - Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q4 2020.
Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12,759,585 shares
of 42,194,093 outstanding shares and own 30% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (3,245,035 shares), RTW INVESTMENTS, LP (2,463,601 shares), FRAZIER MANAGEMENT LLC (1,917,157 shares), Cormorant Asset Management, LP (1,714,269 shares), PERCEPTIVE ADVISORS LLC (1,296,416 shares), TimesSquare Capital Management, LLC (464,600 shares), BlackRock Inc. (322,423 shares), VANGUARD GROUP INC (270,891 shares), SANDS CAPITAL MANAGEMENT, LLC (260,000 shares), and Ensign Peak Advisors, Inc (200,000 shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.